

Company Overview

CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada.

Seminal Clinical Trial in Healthy Adults Demonstrates Promising Preliminary Evidence of PlusCBD™ Oil in Sleep, Wellness, and Weight-Loss Applications

Jun 17 2019, 1:05 PM EDT

CV Sciences, Inc. to Present at the Oppenheimer 19th Annual Consumer Conference

Jun 13 2019, 8:45 AM EDT

CV Sciences, Inc. Announces New Distribution With Kroger and Expands Its Offering of Topical Products

Jun 12 2019, 12:00 PM EDT

Stock Overview

Symbol	CVSI
Exchange	OTCQB
Market Cap	404.99m
Last Price	\$4.105
52-Week	\$1.39 - \$9.20

Investor Relations

ICR, Inc.
Scott Van Winkle
T: 617-956-6736
CVSciences@icrinc.com

06/18/2019 03:59 PM EDT

Management Team

Joseph Dowling

Chief Executive Officer

Joerg Grasser

Chief Financial Officer

Michael J. Mona, III

Co-Founder & Chief Operating Officer

Stuart Tomc

Vice President, Human Nutrition

Dr. Douglas MacKay, N.D.

Senior Vice President of Scientific and Regulatory Affairs

CV Sciences, Inc.

2688 S Rainbow Blvd
Suite B
Las Vegas, NV 89146

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.